Literature DB >> 4605071

Rifampicin plus isoniazid, rifampicin plus PAS, and isoniazid plus PAS in the initial treatment of pulmonary tuberculosis. A controlled multicenter clinical trial.

J Tousek, R Votruba.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4605071     DOI： 10.1159/000221808

Source DB:  PubMed          Journal:  Chemotherapy        ISSN： 0009-3157            Impact factor:   2.544


× No keyword cloud information.
  2 in total

Review 1.  Tuberculosis: 11. Nosocomial disease.

Authors:  K Schwartzman; D Menzies
Journal:  CMAJ       Date:  1999-11-16       Impact factor: 8.262

Review 2.  Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Authors:  W J Burman; K Gallicano; C Peloquin
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.